Literature DB >> 12517250

Novel therapies for the treatment of inflammatory airway disease.

David J Hele1, Maria G Belvisi.   

Abstract

Asthma and chronic obstructive pulmonary disease (COPD) are diseases of the airways with an underlying inflammatory component. The prevalence and healthcare burden of asthma and COPD is still rising and is predicted to continue to rise in the current century. The beta-agonists and corticosteroids form the basis of the treatments available to alleviate the symptoms of asthma, whereas the treatments available for COPD have been shown to have a limited effect on slowing the progression of the disease. Asthma and COPD are both in need of novel, safe treatments to tackle the underlying inflammation that characterises their pathology. The inflammatory processes inherent in asthma and COPD provide the opportunity for innovative drug research. This review will outline the new approaches and targets being investigated, which may provide opportunities for novel therapeutic interventions in these debilitating diseases.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12517250     DOI: 10.1517/13543784.12.1.5

Source DB:  PubMed          Journal:  Expert Opin Investig Drugs        ISSN: 1354-3784            Impact factor:   6.206


  5 in total

1.  Use of a soluble epoxide hydrolase inhibitor in smoke-induced chronic obstructive pulmonary disease.

Authors:  Lei Wang; Jun Yang; Lei Guo; Dale Uyeminami; Hua Dong; Bruce D Hammock; Kent E Pinkerton
Journal:  Am J Respir Cell Mol Biol       Date:  2011-12-28       Impact factor: 6.914

2.  Bioactive lipid profiling reveals drug target engagement of a soluble epoxide hydrolase inhibitor in a murine model of tobacco smoke exposure.

Authors:  Malin L Nording; Jun Yang; Laura Hoang; Vanessa Zamora; Dale Uyeminami; Imelda Espiritu; Kent E Pinkerton; Bruce D Hammock; Ayala Luria
Journal:  J Metabolomics       Date:  2015-04-04

Review 3.  COPD: the patient perspective.

Authors:  Paul W Jones; Henrik Watz; Emiel F M Wouters; Mario Cazzola
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2016-02-19

4.  The Isosteroid Alkaloid Imperialine from Bulbs of Fritillaria cirrhosa Mitigates Pulmonary Functional and Structural Impairment and Suppresses Inflammatory Response in a COPD-Like Rat Model.

Authors:  Dongdong Wang; Qingdan Du; Houcong Li; Shu Wang
Journal:  Mediators Inflamm       Date:  2016-07-20       Impact factor: 4.711

5.  Increased expression of Siglec-9 in chronic obstructive pulmonary disease.

Authors:  Zhilin Zeng; Miao Li; Meijia Wang; Xiaomei Wu; Qinghai Li; Qin Ning; Jianping Zhao; Yongjian Xu; Jungang Xie
Journal:  Sci Rep       Date:  2017-08-31       Impact factor: 4.379

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.